VAR2 Pharmaceuticals

... is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications.

About VAR2 Pharmaceuticals

VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.

The technology is based on groundbreaking discoveries made by researchers at University of Copenhagen, Denmark, in collaboration with partners at University of British Columbia, Canada.

Read more
16 August 2018
Uncategorized
Today our researchers at Copenhagen University and University of British Columbia together with academic partners in United Kingdom, Australia and Taiwan published an article in Nature Communications that demonstrates that rVAR2 indeed can be used as a tool to capture and isolate circulating tumour ...
14 August 2018
Uncategorized

Check out the article about VAR2 Pharmaceuticals and VarCT Diagnostics here.

28 May 2018
Uncategorized
VAR2 will be represented by its COO, Andreas Linderoth Norlin, at this year's BIO International Convention taking place in Boston 4th to 7th June. We look forward to a great program and many exciting meetings with old and new partners in the biopharma business. See you there! ...
13 April 2018
Uncategorized
VAR2 Pharmaceuticals founder and member of the Board of Directors, Prof. Poul Sorensen, will give a talk with the title “Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers” on Saturady April 14th at the AACR meeting in Chicago, IL. The presentation will highlight s...

Our Investors

VAR2 Pharmaceuticals is owned by the inventor group and University of Copenhagen, and we are financed by private investors.

Read More

Want to be a partner?

To discuss a potential partnership opportunity with VAR2 Pharmaceuticals please contact us

Read more